| Schedule of Anti-dilutive Financial Instruments |
The calculation of diluted loss per
share for the nine and three months ended September 30, 2024 and September 30, 2023, does not include the shares underlying
the following financial instruments because their effect would be anti-dilutive:
| |
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
| |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
| Options |
|
|
2,041,139 |
|
|
|
591,034 |
|
|
|
2,062,650 |
|
|
|
591,034 |
|
| Warrants |
|
|
12,646,132 |
|
|
|
921,251 |
|
|
|
1,825,281 |
|
|
|
921,251 |
|
| Contingent shares |
|
|
200,000 |
|
|
|
400,000 |
|
|
|
200,000 |
|
|
|
400,000 |
|
| Redeemable Convertible Preferred Shares |
|
|
14,773,500 |
|
|
|
- |
|
|
|
14,773,500 |
|
|
|
- |
|
|
| Schedule of Basic and Diluted Loss (earnings) Per Share |
The following table presents the computation
of basic and diluted loss (earnings) per share:
| |
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
| |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
| Basic loss (earnings) per share of common stock |
|
|
|
|
|
|
|
|
|
|
|
|
| Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
| Net loss (income) |
|
|
(9,642 |
) |
|
|
7,906 |
|
|
|
3,214 |
|
|
|
20,678 |
|
| Amount allocated to Redeemable Convertible Preferred Shares |
|
|
(4,575 |
) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Net loss (income) attributable to shares of common stock |
|
|
(5,067 |
) |
|
|
7,906 |
|
|
|
3,214 |
|
|
|
20,678 |
|
| Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares of common stock outstanding |
|
|
16,365,824 |
|
|
|
4,597,403 |
|
|
|
9,943,968 |
|
|
|
3,951,624 |
|
| Number of shares upon Pre-Funded Warrants exercise |
|
|
- |
|
|
|
1,461,073 |
|
|
|
- |
|
|
|
867,736 |
|
| Number of shares upon Fully vested Warrants exercise |
|
|
298 |
|
|
|
298 |
|
|
|
298 |
|
|
|
298 |
|
| Total weighted-average number of shares of common stock, shares upon Pre-Funded Warrants and Fully vested Warrants exercise used in computing basic loss (earnings) per share |
|
|
16,366,122 |
|
|
|
6,058,774 |
|
|
|
9,944,267 |
|
|
|
4,819,658 |
|
| Basic loss (earnings) per share of common stock |
|
|
(0.31 |
) |
|
|
1.30 |
|
|
|
0.32 |
|
|
|
4.29 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diluted net loss per share of common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net loss (income) |
|
|
(9,642 |
) |
|
|
7,906 |
|
|
|
3,214 |
|
|
|
20,678 |
|
| Change in fair value of Private Placement Warrants |
|
|
- |
|
|
|
- |
|
|
|
24,417 |
|
|
|
- |
|
| Diluted net loss |
|
|
(9,642 |
) |
|
|
7,906 |
|
|
|
27,631 |
|
|
|
20,678 |
|
| Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted-average number of shares of common stock outstanding |
|
|
16,366,122 |
|
|
|
6,058,774 |
|
|
|
9,944,267 |
|
|
|
4,819,658 |
|
| Private Placement Warrants |
|
|
- |
|
|
|
- |
|
|
|
1,350,613 |
|
|
|
- |
|
| Options |
|
|
21,511 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Total weighted-average number of shares of common stock outstanding, after giving effect to dilutive securities |
|
|
16,387,633 |
|
|
|
6,058,774 |
|
|
|
11,294,880 |
|
|
|
4,819,658 |
|
| Diluted net loss per share of common stock |
|
|
(0.31 |
) |
|
|
1.30 |
|
|
|
2.45 |
|
|
|
4.29 |
|
|